fluticasone (Cutivate)

Subscribe to Selected New Research on fluticasone

1080 relevant articles (218 outcomes, 409 trials/studies) found for this Drug

Description: used in nasal spray for seasonal allergic rhinitis

Also Known As:

Cutivate; Flixonase; Flixotide; Flonase; Flovent; fluticasone propionate; S-(Fluoromethyl) 6a,9-difluoro-11b,17-dihydroxy-16a-methyl-3-oxoandrosta-1,4-diene-17b-carbothioate

Relationship Network

Drug Context: Research Results

Polycyclic Compounds: 58

Experts

1.	Jones, P W: 11 articles (01/2007 - 05/2000)
2.	Emmett, Amanda: 8 articles (08/2008 - 01/2002)
3.	Lipworth, Brian J: 8 articles (06/2007 - 10/2002)
4.	Lasserson, T J: 8 articles (01/2007 - 01/2004)
5.	Dorinsky, Paul: 8 articles (01/2006 - 01/2002)
6.	Philpot, Edward E: 6 articles (02/2008 - 07/2002)
7.	Bateman, E D: 6 articles (01/2008 - 02/2001)
8.	Adams, N: 6 articles (01/2007 - 01/2001)
9.	Rickard, Kathleen: 6 articles (08/2005 - 01/2002)
10.	Knobil, Katharine: 5 articles (08/2008 - 01/2004)

Related Diseases

1.	Asthma (Bronchial Asthma) 05/01/1996 - "BACKGROUND: Fluticasone propionate is a potent inhaled corticosteroid that is effective in improving pulmonary function and symptoms in patients with asthma" 04/01/1997 - "The probability of patients remaining in the study over time without developing signs of exacerbating asthma was significantly greater in the fluticasone propionate groups than in the placebo group (P = .001)" 07/01/2002 - "Fluticasone-treated patients had significantly greater increases in the mean percentages of symptom-free days (22% vs. 8%, P <0.001), rescue-free days (23% vs. 10%, P = 0.002), nights with uninterrupted sleep (<1% vs. -5%, P = 0.006), and fewer asthma exacerbations (1% vs. 6%, P = 0.005)" 10/01/2001 - "Children with a family history of asthma (n = 213) also had a significantly greater increase in days without symptoms after fluticasone propionate (11% to 54%) compared with after placebo (7% to 35%, P =.002) and a significantly higher proportion of exacerbation-free patients (61% to 76%, P =.02)" 09/01/2001 - "Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate." Get all the results and reference details, order at left...
2.	Rhinitis 01/01/2000 - "The most commonly prescribed nasal steroid, fluticasone, has been shown to be effective in treating rhinitis and in improving patients' quality of life" 03/01/1997 - "Fluticasone propionate is a fluorinated steroid reported to be highly effective when used topically in the nose for seasonal and perennial allergic and nonallergic rhinitis" 05/01/1997 - "The intranasal corticosteroid fluticasone propionate is an effective agent for the treatment of rhinitis, demonstrating potent local anti-inflammatory activity and little, if any, systemic activity" 03/01/2001 - "The study suggests that fluticasone propionate nasal spray can be beneficial in the treatment of patients with rhinitis medicamentosa." 02/01/1996 - "Fluticasone propionate aqueous nasal spray: a well-tolerated and effective treatment for children with perennial rhinitis." Get all the results and reference details, order at left...
3.	Seasonal Allergic Rhinitis (Hay Fever) 06/01/1993 - "BACKGROUND: Fluticasone propionate aqueous nasal spray, a new potent corticosteroid, is effective when given once or twice daily for seasonal allergic rhinitis" 10/01/1994 - "RESULTS: Intranasal fluticasone propionate, 200 micrograms or 100 micrograms once daily, was significantly more effective than placebo in the treatment of seasonal allergic rhinitis in children" 08/01/1996 - "BACKGROUND: Fluticasone propionate aqueous nasal spray, a new topical corticosteroid, has been proved to be an effective treatment for seasonal allergic rhinitis" 02/01/1994 - "Fluticasone aqueous nasal spray was effective in relieving nasal symptoms in adolescents and adults with seasonal allergic rhinitis" 10/01/1993 - "In children as young as 4 years, 100 micrograms of fluticasone propionate aqueous nasal spray given once daily is as effective as 200 micrograms given once daily, the usual adult dose for the treatment of seasonal allergic rhinitis" Get all the results and reference details, order at left...
4.	Chronic Obstructive Pulmonary Disease (COPD) 12/01/2003 - "Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease" 09/01/2002 - "CONCLUSION: Fluticasone propionate given for 3 months to patients with COPD has selective effects on the inflammatory cells in the bronchial mucosa: the reduction in mast cell numbers may account for the improvement in symptoms over this time." 11/01/2008 - "METHODS: A double-blind, placebo-controlled, randomized 2:1 study of fluticasone propionate (FP), 500 microg twice daily versus placebo over 6 months was performed in subjects with mild to moderate COPD" 01/01/2007 - "METHODS: In a pragmatic randomised, double-blind, placebo-controlled trial in 31 practices, 260 COPD patients stopped their usual ICS (median duration of use 8 years) and were allocated to 500 mcg fluticasone propionate twice daily (n = 128), or placebo (n = 132)" 01/01/2006 - "This study determined the cost effectiveness of withdrawing fluticasone propionate (FP) in outpatients with COPD" Get all the results and reference details, order at left...
5.	Inflammation 05/01/2003 - "Therefore, very low doses of FP (50 microg b.i.d.) are effective in maintaining for 3 months a good control of the disease in asthmatics already stable under high-dose fluticasone, considering both clinical and functional outcomes and markers of airway inflammation." 04/01/1998 - "In conclusion, this study demonstrated that topical fluticasone propionate is effective in the treatment of mucosal inflammation induced by NAC" 06/01/2007 - "A multicenter, open-label, randomized comparison of suppressive effects on asthmatic inflammation of lower airways and improved effects on health-related QOL between HFA-BDP and fluticasone propionate]" 01/06/2008 - "farinae can induce airway remodeling through Th2-type inflammation, and that fluticasone propionate inhibits D" 01/01/2008 - "Intranasal administration of fluticasone inhibited the development of eosinophilic inflammation, and importantly, thickening of the smooth muscle layer" Get all the results and reference details, order at left...
125 Diseases and 1080 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	salmeterol (Serevent)
2.	Budesonide (Pulmicort)
3.	Beclomethasone (Beclometasone)
4.	montelukast (Singulair)
5.	Albuterol (Salbutamol)
6.	Adrenal Cortex Hormones (Corticosteroids)
7.	fluticasone (Cutivate)
8.	formoterol (Oxis)
9.	fluticasone-salmeterol combination (Advair)
10.	ciclesonide
387 Drugs and Important Bio-Agents and 762 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Nebulizers and Vaporizers (Inhaler)
2.	Metered Dose Inhalers (Metered Dose Inhaler)
3.	Respiratory Therapy (Therapy, Respiratory)
4.	Drug Therapy (Chemotherapy)
5.	Stem Cell Transplantation
17 Therapies and Procedures and 142 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>